|
Research update: GPC Biotech AG October 15, 2007  Weighing risks against reward GPC Biotech is almost a one-product company with Satraplatin. In July 2007 US FDA aproval for a second-line treatment of hormone-refractory prostate cancer was unexpectedly delayed. The shares plunged by 65%. The group hopes analysis of survival results will secure US FDA approval in 2008 and in Europe in 2008. Extended clinical trials. Survival data for Satraplatin is expected within the next three months. If positive, it should have a major impact on the share... ...Subscribe to VISCARDI Research... |
|
Research update: GPC Biotech AG September 29, 2006 On schedule GPC Biotech has announced a successful completion of phase three clinical trials of Satraplatin for the second-line treatment of hormone-refactory prostate cancer in combination with Prednisone. The group aims to file a New Drug Application... ...Subscribe to VISCARDI Research... |
|
Research note: GPC Biotech AG March 09, 2006 Reduced financial risks, but closer to fair value GPC Biotech is focused on developing platinum-based cancer treatments. The most advanced compound is Satraplatin, which if approved, could be on sale in ... ...Subscribe to VISCARDI Research... |